ProCE Banner Activity

CME

Targeted Therapies for Bladder Cancer and Beyond: Overview and Current Status of FGFR Inhibitors

Text Module

Gain expert insights on targeting FGFR signaling in bladder cancer and other malignancies.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: June 14, 2021

Expiration: June 13, 2022

No longer available for credit.

Share

Faculty

Ignacio Duran

Ignacio Duran, MD, PhD

Associate Professor
GU Oncology Program Leader
Department of Medical Oncology
Hospital Universitario Marques de Valdecilla-Idival
Santander, Spain

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Janssen Pharmaceutica NV

Target Audience

This activity is intended for global oncologists, pathologists, and other healthcare professionals who care for patients with bladder cancer and other tumor treatments with FGFR signaling in development.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the characteristics of current and emerging therapeutic strategies to target FGFR signaling in cancer
  • Discuss the prognostic and potential predictive implications for FGFR genetic alteration testing in cancer
  • Apply recent safety and efficacy data to guide use of FGFR inhibitors in molecularly selected patients with bladder cancer carrying FGFR genomic alterations
  • Manage adverse events associated with the use of FGFR inhibitors in the treatment of patients with cancer and effectively prioritize clinical trial opportunities for eligible patients

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Ignacio Duran, MD, PhD

Associate Professor
GU Oncology Program Leader
Department of Medical Oncology
Hospital Universitario Marques de Valdecilla-Idival
Santander, Spain

Ignacio Duran, MD, PhD, has disclosed that he has received consulting fees from Astellas, Bristol-Myers Squibb, Ipsen, Janssen, Merck, MSD, Pharmacyclics, Roche/Genentech, and Seattle Genetics; fees for non CME/CE services from Bayer, Bristol-Myers Squibb, EUSA, Ipsen, Janssen, and Roche/Genentech; and other financial or material support from AstraZeneca.

Staff Disclosure

Staff

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 14, 2021, through June 13, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge and competence of medical oncologists, pathologists, and other healthcare professionals in assessing FGFR alterations and using novel FGFR-targeted therapies in the treatment of patients with cancer.